BERLIN, BOSTON, REYKJAVIK, 19 May 2022 – International digital therapeutics innovator, Sidekick Health, today announces the launch of an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies. Sidekick and Pfizer will be rolling out their integrated digital therapeutics offering, launching first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022. This marks the next phase of a growing relationship to develop digital patient support programs globally, including expansion into 24 markets by 2024.
The Challenge of Living with Atopic Dermatitis
AD is an inﬂammatory, pruritic, chronic, or chronically relapsing skin disease that affects up to 14% of adults worldwide. People living with moderate to severe AD often have to deal with constant and relentless itching, leading to sleep deprivation, increased stress and anxiety that affects the quality of their lives.
However, one of the challenges of effectively treating AD is that patients’ adherence to treatment tends to be low. Sidekick’s digital therapeutics platform addresses this using gamification principles, behavioral economics, and artificial intelligence (AI) to deliver treatment through dynamic care pathways that help inspire lasting behavioral change, positively impacting health outcomes.
By reducing stress, improving sleep quality, and promoting other lifestyle factors designed to improve the quality of life for people living with AD, Sidekick’s digital patient support program has demonstrated the potential to make a meaningful impact. A recent feasibility study showed medication adherence had increased in 83% of patients using the app to manage their chronic illnesses.
“We are extremely excited to be entering the next phase in our ongoing relationship with Pfizer,” comments Dr. Tryggvi Thorgeirsson, CEO and Co-Founder of Sidekick. “At Sidekick, it’s always been our ambition to help as many people as possible to make long-lasting improvements to lifestyle behaviors and improve their quality of life. Our work with Pfizer better enables us to reach our goal of bringing digital therapeutics into the homes of people around the world.”